Issue 1/2020
Content (139 Articles)
A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer
Iain R. Macpherson, Pavlina Spiliopoulou, Saeed Rafii, Matilde Saggese, Richard D. Baird, Javier Garcia-Corbacho, Antoine Italiano, Jacques Bonneterre, Mario Campone, Nicola Cresti, John Posner, Yousuke Takeda, Akinori Arimura, James Spicer
Impact of aromatase inhibitor treatment on global gene expression and its association with antiproliferative response in ER+ breast cancer in postmenopausal patients
Qiong Gao, Elena López-Knowles, Maggie Chon U. Cheang, James Morden, Ricardo Ribas, Kally Sidhu, David Evans, Vera Martins, Andrew Dodson, Anthony Skene, Chris Holcombe, Elizabeth Mallon, Abigail Evans, Judith M. Bliss, John Robertson, Ian Smith, Lesley-Ann Martin, Mitch Dowsett
Anillin regulates breast cancer cell migration, growth, and metastasis by non-canonical mechanisms involving control of cell stemness and differentiation
Dongdong Wang, Nayden G. Naydenov, Mikhail G. Dozmorov, Jennifer E. Koblinski, Andrei I. Ivanov
A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer
Lori J. Goldstein, Raymond P. Perez, Denise Yardley, Linda K. Han, James M. Reuben, Hui Gao, Susan McCanna, Beth Butler, Pier Adelchi Ruffini, Yi Liu, Roberto R. Rosato, Jenny C. Chang
Nutrient-wide association study of 92 foods and nutrients and breast cancer risk
Alicia K. Heath, David C. Muller, Piet A. van den Brandt, Nikos Papadimitriou, Elena Critselis, Marc Gunter, Paolo Vineis, Elisabete Weiderpass, Guy Fagherazzi, Heiner Boeing, Pietro Ferrari, Anja Olsen, Anne Tjønneland, Patrick Arveux, Marie-Christine Boutron-Ruault, Francesca Romana Mancini, Tilman Kühn, Renée Turzanski-Fortner, Matthias B. Schulze, Anna Karakatsani, Paschalis Thriskos, Antonia Trichopoulou, Giovanna Masala, Paolo Contiero, Fulvio Ricceri, Salvatore Panico, Bas Bueno-de-Mesquita, Marije F. Bakker, Carla H. van Gils, Karina Standahl Olsen, Guri Skeie, Cristina Lasheras, Antonio Agudo, Miguel Rodríguez-Barranco, Maria-José Sánchez, Pilar Amiano, María-Dolores Chirlaque, Aurelio Barricarte, Isabel Drake, Ulrika Ericson, Ingegerd Johansson, Anna Winkvist, Tim Key, Heinz Freisling, Mathilde His, Inge Huybrechts, Sofia Christakoudi, Merete Ellingjord-Dale, Elio Riboli, Konstantinos K. Tsilidis, Ioanna Tzoulaki
Identification and transfer of spatial transcriptomics signatures for cancer diagnosis
Niyaz Yoosuf, José Fernández Navarro, Fredrik Salmén, Patrik L. Ståhl, Carsten O. Daub
p66ShcA functions as a contextual promoter of breast cancer metastasis
Kyle Lewis, Alex Kiepas, Jesse Hudson, Julien Senecal, Jacqueline R. Ha, Elena Voorand, Matthew G. Annis, Valerie Sabourin, Ryuhjin Ahn, Rachel La Selva, Sébastien Tabariès, Brian E. Hsu, Matthew J. Siegel, Matthew Dankner, Eduardo Cepeda Canedo, Mathieu Lajoie, Ian R. Watson, Claire M. Brown, Peter M. Siegel, Josie Ursini-Siegel
Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers
Nasim Mavaddat, Antonis C. Antoniou, Thea M. Mooij, Maartje J. Hooning, Bernadette A. Heemskerk-Gerritsen, Catherine Noguès, Lilian Laborde, Emmanuel Breysse, Dominique Stoppa-Lyonnet, Marion Gauthier-Villars, Bruno Buecher, Olivier Caron, Emmanuelle Fourme-Mouret, Jean-Pierre Fricker, Christine Lasset, Valérie Bonadona, Pascaline Berthet, Laurence Faivre, Elisabeth Luporsi, Véronique Mari, Laurence Gladieff, Paul Gesta, Hagay Sobol, François Eisinger, Catherine Noguès, Michel Longy, Catherine Dugast, Chrystelle Colas, Isabelle Coupier, Pascal Pujol, Carole Corsini, Alain Lortholary, Philippe Vennin, Claude Adenis, Tan Dat Nguyen, Capucine Delnatte, Julie Tinat, Isabelle Tennevet, Jean-Marc Limacher, Christine Maugard, Yves-Jean Bignon, Liliane Demange, Clotilde Penet, Hélène Dreyfus, Odile Cohen-Haguenauer, Laurence Venat-Bouvet, Dominique Leroux, Hélène Dreyfus, Hélène Zattara-Cannoni, Sandra Fert-Ferrer, Odile Bera, Catherine Noguès, Marion Gauthier-Villars, Olivier Caron, Paul Gesta, Pascal Pujol, Alain Lortholary, Steve Ellis, Daniel Barrowdale, Debra Frost, D. Gareth Evans, Louise Izatt, Julian Adlard, Ros Eeles, Carole Brewer, Marc Tischkowitz, Alex Henderson, Jackie Cook, Diana Eccles, F. B. L. Hogervorst, J. M. Collée, C. J. van Asperen, A. R. Mensenkamp, M. G. E. M. Ausems, H. E. J. Meijers-Heijboer, K. van Engelen, M. J. Blok, J. C. Oosterwijk, J. Verloop, E. van den Broek, Klaartje van Engelen, Marian J. E. Mourits, Margreet G. E. M. Ausems, Linetta B. Koppert, John L. Hopper, Esther M. John, Wendy K. Chung, Irene L. Andrulis, Mary B. Daly, Saundra S. Buys, Javier Benitez, Trinidad Caldes, Anna Jakubowska, Jacques Simard, Christian F. Singer, Yen Tan, Edith Olah, Marie Navratilova, Lenka Foretova, Anne-Marie Gerdes, Marie-José Roos-Blom, Flora E. Van Leeuwen, Brita Arver, Håkan Olsson, Rita K. Schmutzler, Christoph Engel, Karin Kast, Kelly-Anne Phillips, Mary Beth Terry, Roger L. Milne, David E. Goldgar, Matti A. Rookus, Nadine Andrieu, Douglas F. Easton
Correction to: NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer
Samuel A. Jacobs, André Robidoux, Jame Abraham, José Manuel Pérez-Garcia, Nicla La Verde, James M. Orcutt, Marina E. Cazzaniga, Fanny Piette, Silvia Antolín, Elena Aguirre, Javier Cortes, Antonio Llombart-Cussac, Serena Di Cosimo, Rim S. Kim, Huichen Feng, Corey Lipchik, Peter C. Lucas, Ashok Srinivasan, Ying Wang, Nan Song, Patrick G. Gavin, April D. Balousek, Soonmyung Paik, Carmen J. Allegra, Norman Wolmark, Katherine L. Pogue-Geile
Long-term risk of ischemic heart disease after adjuvant radiotherapy in breast cancer: results from a large population-based cohort
Anna-Karin Wennstig, Charlotta Wadsten, Hans Garmo, Irma Fredriksson, Carl Blomqvist, Lars Holmberg, Greger Nilsson, Malin Sund
Serum exosomal-annexin A2 is associated with African-American triple-negative breast cancer and promotes angiogenesis
Pankaj Chaudhary, Lee D. Gibbs, Sayantan Maji, Cheryl M. Lewis, Sumihiro Suzuki, Jamboor K. Vishwanatha
A deep learning image-based intrinsic molecular subtype classifier of breast tumors reveals tumor heterogeneity that may affect survival
Mustafa I. Jaber, Bing Song, Clive Taylor, Charles J. Vaske, Stephen C. Benz, Shahrooz Rabizadeh, Patrick Soon-Shiong, Christopher W. Szeto
Prognostic DNA methylation markers for hormone receptor breast cancer: a systematic review
Tim C. de Ruijter, Frank van der Heide, Kim M. Smits, Maureen J. Aarts, Manon van Engeland, Vivianne C. G. Heijnen
Correction to: Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer
Sunil Pancholi, Mariana Ferreira Leal, Ricardo Ribas, Nikiana Simigdala, Eugene Schuster, Sophie Chateau-Joubert, Lila Zabaglo, Margaret Hills, Andrew Dodson, Qiong Gao, Stephen R. Johnston, Mitch Dowsett, Sabina C. Cosulich, Elisabetta Marangoni, Lesley-Ann Martin
HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
Alberto Ocaña, Eitan Amir, Atanasio Pandiella
ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis
Adi Zundelevich, Maya Dadiani, Smadar Kahana-Edwin, Amit Itay, Tal Sella, Moran Gadot, Karen Cesarkas, Sarit Farage-Barhom, Efrat Glick Saar, Eran Eyal, Nitzan Kol, Anya Pavlovski, Nora Balint-Lahat, Daniela Dick-Necula, Iris Barshack, Bella Kaufman, Einav Nili Gal-Yam
Letter to the editor: a response to Ming’s study on machine learning techniques for personalized breast cancer risk prediction
Daniele Giardiello, Antonis C. Antoniou, Luigi Mariani, Douglas F. Easton, Ewout W. Steyerberg
Immunohistochemical analysis of adipokine and adipokine receptor expression in the breast tumor microenvironment: associations of lower leptin receptor expression with estrogen receptor-negative status and triple-negative subtype
Adana A. M. Llanos, Yong Lin, Wenjin Chen, Song Yao, Jorden Norin, Marina A. Chekmareva, Coral Omene, Lei Cong, Angela R. Omilian, Thaer Khoury, Chi-Chen Hong, Shridar Ganesan, David J. Foran, Michael Higgins, Christine B. Ambrosone, Elisa V. Bandera, Kitaw Demissie
Correction to: Timing of pubertal stages and breast cancer risk: the Breakthrough Generations Study
Danielle H. Bodicoat, Minouk J. Schoemaker, Michael E. Jones, Emily McFadden, James Griffin, Alan Ashworth, Anthony J. Swerdlow
Clinical applications of polygenic breast cancer risk: a critical review and perspectives of an emerging field
Tatiane Yanes, Mary-Anne Young, Bettina Meiser, Paul A. James
TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer
Christos Vaklavas, Brian S. Roberts, Katherine E. Varley, Nancy U. Lin, Minetta C. Liu, Hope S. Rugo, Shannon Puhalla, Rita Nanda, Anna Maria Storniolo, Lisa A. Carey, Mansoor N. Saleh, Yufeng Li, Jennifer F. Delossantos, William E. Grizzle, Albert F. LoBuglio, Richard M. Myers, Andres Forero-Torres
Circulating 27-hydroxycholesterol and breast cancer tissue expression of CYP27A1, CYP7B1, LXR-β, and ERβ: results from the EPIC-Heidelberg cohort
Charlotte Le Cornet, Britta Walter, Disorn Sookthai, Theron S. Johnson, Tilman Kühn, Ester Herpel, Rudolf Kaaks, Renée T. Fortner
Correction to: Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers
Nasim Mavaddat, Antonis C. Antoniou, Thea M. Mooij, Maartje J. Hooning, Bernadette A. Heemskerk-Gerritsen, Catherine Noguès, Marion Gauthier-Villars, Olivier Caron, Paul Gesta, Pascal Pujol, Alain Lortholary, Daniel Barrowdale, Debra Frost, D. Gareth Evans, Louise Izatt, Julian Adlard, Ros Eeles, Carole Brewer, Marc Tischkowitz, Alex Henderson, Jackie Cook, Diana Eccles, Klaartje van Engelen, Marian J. E. Mourits, Margreet G. E. M. Ausems, Linetta B. Koppert, John L. Hopper, Esther M. John, Wendy K. Chung, Irene L. Andrulis, Mary B. Daly, Saundra S. Buys, Javier Benitez, Trinidad Caldes, Anna Jakubowska, Jacques Simard, Christian F. Singer, Yen Tan, Edith Olah, Marie Navratilova, Lenka Foretova, Anne-Marie Gerdes, Marie-José Roos-Blom, Flora E. Van Leeuwen, Brita Arver, Håkan Olsson, Rita K. Schmutzler, Christoph Engel, Karin Kast, Kelly-Anne Phillips, Mary Beth Terry, Roger L. Milne, David E. Goldgar, Matti A. Rookus, Nadine Andrieu, Douglas F. Easton
MiR-7 reduces the BCSC subset by inhibiting XIST to modulate the miR-92b/Slug/ESA axis and inhibit tumor growth
Miao Li, Meng Pan, Chengzhong You, Fengshu Zhao, Di Wu, Mei Guo, Hui Xu, Fangfang Shi, Danfeng Zheng, Jun Dou
Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies
Johannes Ettl, Seock-Ah Im, Jungsil Ro, Norikazu Masuda, Marco Colleoni, Patrick Schnell, Eustratios Bananis, Dongrui R. Lu, Massimo Cristofanilli, Hope S. Rugo, Richard S. Finn
Correction to: ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis
Adi Zundelevich, Maya Dadiani, Smadar Kahana-Edwin, Amit Itay, Tal Sella, Moran Gadot, Karen Cesarkas, Sarit Farage-Barhom, Efrat Glick Saar, Eran Eyal, Nitzan Kol, Anya Pavlovski, Nora Balint-Lahat, Daniela Dick-Necula, Iris Barshack, Bella Kaufman, Einav Nili Gal-Yam
Diffuse optical spectroscopic imaging reveals distinct early breast tumor hemodynamic responses to metronomic and maximum tolerated dose regimens
Anup Tank, Hannah M. Peterson, Vivian Pera, Syeda Tabassum, Anais Leproux, Thomas O’Sullivan, Eric Jones, Howard Cabral, Naomi Ko, Rita S. Mehta, Bruce J. Tromberg, Darren Roblyer
High hepatocyte growth factor expression in primary tumor predicts better overall survival in male breast cancer
Si-Qi Qiu, Johan van Rooijen, Hilde H. Nienhuis, Bert van der Vegt, Hetty Timmer-Bosscha, Elise van Leeuwen-Stok, Annemiek M. E. Walenkamp, Carolien H. M. van Deurzen, Geertruida H. de Bock, Elisabeth G. E. de Vries, Carolien P. Schröder
Correction to: Serum exosomal-annexin A2 is associated with African-American triple-negative breast cancer and promotes angiogenesis
Pankaj Chaudhary, Lee D. Gibbs, Sayantan Maji, Cheryl M. Lewis, Sumihiro Suzuki, Jamboor K. Vishwanatha
Immune microenvironment in ductal carcinoma in situ: a comparison with invasive carcinoma of the breast
Milim Kim, Yul Ri Chung, Hyun Jeong Kim, Ji Won Woo, Soomin Ahn, So Yeon Park
Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications
Claudio Vernieri, Francesca Corti, Federico Nichetti, Francesca Ligorio, Sara Manglaviti, Emma Zattarin, Carmen G. Rea, Giuseppe Capri, Giulia V. Bianchi, Filippo de Braud
Breast cancer bone metastases are attenuated in a Tgif1-deficient bone microenvironment
Marie-Therese Haider, Hiroaki Saito, Jennifer Zarrer, Kevin Uzhunnumpuram, Sankari Nagarajan, Vijayalakshmi Kari, Michael Horn-Glander, Stefan Werner, Eric Hesse, Hanna Taipaleenmäki
Letter to the editor: Response to Giardiello D, Antoniou AC, Mariani L, Easton DF, Steyerberg EW
Chang Ming, Valeria Viassolo, Nicole Probst-Hensch, Pierre O. Chappuis, Ivo D. Dinov, Maria C. Katapodi
Tumor sequencing is useful to refine the analysis of germline variants in unexplained high-risk breast cancer families
Cédric Van Marcke, Raphaël Helaers, Anne De Leener, Ahmad Merhi, Céline A. Schoonjans, Jérôme Ambroise, Christine Galant, Paul Delrée, Françoise Rothé, Isabelle Bar, Elsa Khoury, Pascal Brouillard, Jean-Luc Canon, Peter Vuylsteke, Jean-Pascal Machiels, Martine Berlière, Nisha Limaye, Miikka Vikkula, François P. Duhoux
Cetuximab PET delineated changes in cellular distribution of EGFR upon dasatinib treatment in triple negative breast cancer
Brooke N. McKnight, Seongho Kim, Julie L. Boerner, Nerissa T. Viola
Apolipoprotein-mediated regulation of lipid metabolism induces distinctive effects in different types of breast cancer cells
Céline Ben Hassen, Jorge L. Gutierrez-Pajares, Cyrille Guimaraes, Roseline Guibon, Michelle Pinault, Gaëlle Fromont, Philippe G. Frank
Glucocorticoid receptors are required effectors of TGFβ1-induced p38 MAPK signaling to advanced cancer phenotypes in triple-negative breast cancer
Carlos Perez Kerkvliet, Amy R. Dwyer, Caroline H. Diep, Robert H. Oakley, Christopher Liddle, John A. Cidlowski, Carol A. Lange
Insulin resistance contributes to racial disparities in breast cancer prognosis in US women
Emily J. Gallagher, Kezhen Fei, Sheldon M. Feldman, Elisa Port, Neil B. Friedman, Susan K. Boolbol, Brigid Killelea, Melissa Pilewskie, Lydia Choi, Tari King, Anupma Nayak, Rebeca Franco, Daliz Cruz, Irini M. Antoniou, Derek LeRoith, Nina A. Bickell
In utero estrogenic endocrine disruption alters the stroma to increase extracellular matrix density and mammary gland stiffness
Clarissa Wormsbaecher, Andrea R. Hindman, Alex Avendano, Marcos Cortes-Medina, Caitlin E. Jones, Andrew Bushman, Lotanna Onua, Claire E. Kovalchin, Alina R. Murphy, Hannah L. Helber, Ali Shapiro, Kyle Voytovitch, Xingyan Kuang, Renan Aguilar-Valenzuela, Jennifer L. Leight, Jonathan W. Song, Craig J. Burd
Quantitative stain-free imaging and digital profiling of collagen structure reveal diverse survival of triple negative breast cancer patients
Laurent Gole, Joe Yeong, Jeffrey Chun Tatt Lim, Kok Haur Ong, Hao Han, Aye Aye Thike, Yong Cheng Poh, Sidney Yee, Jabed Iqbal, Wanjin Hong, Bernett Lee, Weimiao Yu, Puay Hoon Tan
Functional evaluation of five BRCA2 unclassified variants identified in a Sri Lankan cohort with inherited cancer syndromes using a mouse embryonic stem cell-based assay
Nirmala Sirisena, Kajal Biswas, Teresa Sullivan, Stacey Stauffer, Linda Cleveland, Eileen Southon, Vajira H. W. Dissanayake, Shyam K. Sharan
Investigation of the adolescent female breast transcriptome and the impact of obesity
Adam Burkholder, Dennis Akrobetu, Arun R. Pandiri, Kiki Ton, Sue Kim, Brian I. Labow, Laura C. Nuzzi, Joseph M. Firriolo, Sallie S. Schneider, Suzanne E. Fenton, Natalie D. Shaw
Frequency and spectrum of PIK3CA somatic mutations in breast cancer
Olga Martínez-Sáez, Nuria Chic, Tomás Pascual, Barbara Adamo, Maria Vidal, Blanca González-Farré, Esther Sanfeliu, Francesco Schettini, Benedetta Conte, Fara Brasó-Maristany, Adela Rodríguez, Débora Martínez, Patricia Galván, Ana Belén Rodríguez, Antonio Martinez, Montserrat Muñoz, Aleix Prat
Tumour-infiltrating lymphocytes and response to neoadjuvant letrozole in patients with early oestrogen receptor-positive breast cancer: analysis from a nationwide phase II DBCG trial
Signe Korsgaard Skriver, Maj-Britt Jensen, Ann Soegaard Knoop, Bent Ejlertsen, Anne-Vibeke Laenkholm
Association of TILs with clinical parameters, Recurrence Score® results, and prognosis in patients with early HER2-negative breast cancer (BC)—a translational analysis of the prospective WSG PlanB trial
Cornelia Kolberg-Liedtke, Oleg Gluz, Fred Heinisch, Friedrich Feuerhake, Hans Kreipe, Michael Clemens, Benno Nuding, Wolfram Malter, Toralf Reimer, Rachel Wuerstlein, Monika Graeser, Steve Shak, Ulrike Nitz, Ronald Kates, Matthias Christgen, Nadia Harbeck
Simultaneous targeting of HER family pro-survival signaling with Pan-HER antibody mixture is highly effective in TNBC: a preclinical trial with PDXs
Tejaswini P. Reddy, Dong S. Choi, Ann C. Anselme, Wei Qian, Wen Chen, Johan Lantto, Ivan D. Horak, Michael Kragh, Jenny C. Chang, Roberto R. Rosato
Clinical and functional significance of tumor/stromal ATR expression in breast cancer patients
Mysoon M. Al-Ansari, Maher Al-Saif, Maria Arafah, Abdelmonneim M. Eldali, Asma Tulbah, Taher Al-Tweigeri, Abdelhabib Semlali, Khalid S. Khabar, Abdelilah Aboussekhra
ERα-36 regulates progesterone receptor activity in breast cancer
Henri-Philippe Konan, Loay Kassem, Soleilmane Omarjee, Ausra Surmieliova-Garnès, Julien Jacquemetton, Elodie Cascales, Amélie Rezza, Olivier Trédan, Isabelle Treilleux, Coralie Poulard, Muriel Le Romancer
Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer
Swaathi Jayaraman, Xiaonan Hou, Mary J. Kuffel, Vera J. Suman, Tanya L. Hoskin, Kathryn E. Reinicke, David G. Monroe, Krishna R. Kalari, Xiaojia Tang, Megan A. Zeldenrust, Jingfei Cheng, Elizabeth S. Bruinsma, Sarah A. Buhrow, Renee M. McGovern, Stephanie L. Safgren, Chad A. Walden, Jodi M. Carter, Joel M. Reid, James N. Ingle, Matthew M. Ames, John R. Hawse, Matthew P. Goetz
Correction to: A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer
Lori J. Goldstein, Raymond P. Perez, Denise Yardley, Linda K. Han, James M. Reuben, Hui Gao, Susan McCanna, Beth Butler, Pier Adelchi Ruffini, Yi Liu, Roberto R. Rosato, Jenny C. Chang
Modeling the natural history of ductal carcinoma in situ based on population data
Sarocha Chootipongchaivat, Nicolien T. van Ravesteyn, Xiaoxue Li, Hui Huang, Harald Weedon-Fekjær, Marc D. Ryser, Donald L. Weaver, Elizabeth S. Burnside, Brandy M. Heckman-Stoddard, Harry J. de Koning, Sandra J. Lee
Efficacy of neoadjuvant endocrine therapy compared with neoadjuvant chemotherapy in pre-menopausal patients with oestrogen receptor-positive and HER2-negative, lymph node-positive breast cancer
Hee Jeong Kim, Woo Chul Noh, Eun Sook Lee, Yong Sik Jung, Lee Su Kim, Wonshik Han, Seok Jin Nam, Gyung -Yub Gong, Hwa Jung Kim, Sei Hyun Ahn
COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris area
Perrine Vuagnat, Maxime Frelaut, Toulsie Ramtohul, Clémence Basse, Sarah Diakite, Aurélien Noret, Audrey Bellesoeur, Vincent Servois, Delphine Hequet, Enora Laas, Youlia Kirova, Luc Cabel, Jean-Yves Pierga, Aurélia Alimi, Muriel Belotti, Okba Bensaoula, Ophélie Bertrand, Geoffroy Bilger, Etienne Brain, Hervé Brisse, Bruno Buecher, Laetitia Chanas, Caroline Chapus, Isabelle Charles-Massar, Pascal Chérel, Gilles Créhange, Christelle Colas, Hélène Delhomelle, Thomas Frederic-Moreau, Emmanuelle Fourme, Pierre Fumoleau, Marion Gauthier-Villars, Olivier Lantz, Sophie Lassalle, Marine Le Mentec, Florence Lerebours, Delphine Loirat, Matthieu Minsat, Pauline Moreau, Antoine de Pauw, Maël Priour, Fabien Reyal, Roman Rouzier, Mary Saad, Claire Saule, Clara Sebbag, Dominique Stoppa-Lyonnet, Anne Tardivon, Silvia Takanen, Dominique Vanjak, Marie-Charlotte Villy, Anne Vincent-Salomon, Mathilde Warcoin, Laurence Bozec, Xavier Paoletti, Paul Cottu, François-Clément Bidard
Risk of early progression according to circulating ESR1 mutation, CA-15.3 and cfDNA increases under first-line anti-aromatase treatment in metastatic breast cancer
Florian Clatot, Anne Perdrix, Ludivine Beaussire, Justine Lequesne, Christelle Lévy, George Emile, Michael Bubenheim, Sigrid Lacaille, Céline Calbrix, Laetitia Augusto, Cécile Guillemet, Cristina Alexandru, Maxime Fontanilles, David Sefrioui, Lucie Burel, Sabine Guénot, Doriane Richard, Nasrin Sarafan-Vasseur, Frédéric Di Fiore
A machine learning model that classifies breast cancer pathologic complete response on MRI post-neoadjuvant chemotherapy
Elizabeth J. Sutton, Natsuko Onishi, Duc A. Fehr, Brittany Z. Dashevsky, Meredith Sadinski, Katja Pinker, Danny F. Martinez, Edi Brogi, Lior Braunstein, Pedram Razavi, Mahmoud El-Tamer, Virgilio Sacchini, Joseph O. Deasy, Elizabeth A. Morris, Harini Veeraraghavan
Ultrafast dynamic contrast-enhanced breast MRI may generate prognostic imaging markers of breast cancer
Natsuko Onishi, Meredith Sadinski, Mary C. Hughes, Eun Sook Ko, Peter Gibbs, Katherine M. Gallagher, Maggie M. Fung, Theodore J. Hunt, Danny F. Martinez, Amita Shukla-Dave, Elizabeth A. Morris, Elizabeth J. Sutton
FAK activates AKT-mTOR signaling to promote the growth and progression of MMTV-Wnt1-driven basal-like mammary tumors
Ritama Paul, Ming Luo, Xueying Mo, Jason Lu, Syn Kok Yeo, Jun-Lin Guan
Enhanced mitochondrial fission suppresses signaling and metastasis in triple-negative breast cancer
Brock A. Humphries, Alyssa C. Cutter, Johanna M. Buschhaus, Yu-Chih Chen, Tonela Qyli, Dilrukshika S. W. Palagama, Samantha Eckley, Tanner H. Robison, Avinash Bevoor, Benjamin Chiang, Henry R. Haley, Saswat Sahoo, Phillip C. Spinosa, Dylan B. Neale, Jagadish Boppisetti, Debashis Sahoo, Pradipta Ghosh, Joerg Lahann, Brian D. Ross, Eusik Yoon, Kathryn E. Luker, Gary D. Luker
Triple-negative breast cancer molecular subtyping and treatment progress
Li Yin, Jiang-Jie Duan, Xiu-Wu Bian, Shi-cang Yu
Racial differences in CD8+ T cell infiltration in breast tumors from Black and White women
Yara Abdou, Kristopher Attwood, Ting-Yuan David Cheng, Song Yao, Elisa V. Bandera, Gary R. Zirpoli, Rochelle Payne Ondracek, Leighton Stein, Wiam Bshara, Thaer Khoury, Christine B. Ambrosone, Angela R. Omilian
Proteogenomic analysis of Inhibitor of Differentiation 4 (ID4) in basal-like breast cancer
Laura A. Baker, Holly Holliday, Daniel Roden, Christoph Krisp, Sunny Z. Wu, Simon Junankar, Aurelien A. Serandour, Hisham Mohammed, Radhika Nair, Geetha Sankaranarayanan, Andrew M. K. Law, Andrea McFarland, Peter T. Simpson, Sunil Lakhani, Eoin Dodson, Christina Selinger, Lyndal Anderson, Goli Samimi, Neville F. Hacker, Elgene Lim, Christopher J. Ormandy, Matthew J. Naylor, Kaylene Simpson, Iva Nikolic, Sandra O’Toole, Warren Kaplan, Mark J. Cowley, Jason S. Carroll, Mark Molloy, Alexander Swarbrick
Age-associated genes in human mammary gland drive human breast cancer progression
Xiang Gu, Bingzhi Wang, Haiyan Zhu, You Zhou, Aaron M. Horning, Tim H-M Huang, Yidong Chen, Peter Houghton, Zhao Lai, Joel E. Michalek, Lu-Zhe Sun
Detection of crown-like structures in breast adipose tissue and clinical outcomes among African-American and White women with breast cancer
Maret L. Maliniak, Aswathy Miriam Cheriyan, Mark E. Sherman, Yuan Liu, Keerthi Gogineni, Jiaqi Liu, Jiabei He, Uma Krishnamurti, Jasmine Miller-Kleinhenz, Ryan Ashiqueali, Jinjing He, Rami Yacoub, Lauren E. McCullough
KLF4 defines the efficacy of the epidermal growth factor receptor inhibitor, erlotinib, in triple-negative breast cancer cells by repressing the EGFR gene
Melyssa S. Roberts, Lindsey J. Anstine, Viviane S. Finke, Benjamin L. Bryson, Bryan M. Webb, Kristen L. Weber-Bonk, Darcie D. Seachrist, Parth R. Majmudar, Ruth A. Keri
Effects of tumor-specific CAP1 expression and body constitution on clinical outcomes in patients with early breast cancer
Malin Bergqvist, Karin Elebro, Malte Sandsveden, Signe Borgquist, Ann H. Rosendahl
New generation breast cancer cell lines developed from patient-derived xenografts
Jessica Finlay-Schultz, Britta M. Jacobsen, Duncan Riley, Kiran V. Paul, Scott Turner, Andrea Ferreira-Gonzalez, J. Chuck Harrell, Peter Kabos, Carol A. Sartorius
Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors
Hua Guo, Qingqing Ding, Yun Gong, Michael Z. Gilcrease, Min Zhao, Jun Zhao, Dawen Sui, Yun Wu, Hui Chen, Hui Liu, Jinxia Zhang, Erika Resetkova, Stacy L. Moulder, Wei-Lien Wang, Lei Huo
Patient treatment and outcome after breast cancer orbital and periorbital metastases: a comprehensive case series including analysis of lobular versus ductal tumor histology
Martin Blohmer, Li Zhu, Jennifer M. Atkinson, Sushil Beriwal, Joshua L. Rodríguez-López, Margaret Rosenzweig, Adam M. Brufsky, George Tseng, Peter C. Lucas, Adrian V. Lee, Steffi Oesterreich, Rachel C. Jankowitz
Correction to: FAK activates AKT-mTOR signaling to promote the growth and progression of MMTV-Wnt1-driven basal-like mammary tumors
Ritama Paul, Ming Luo, Xueying Mo, Jason Lu, Syn Kok Yeo, Jun-Lin Guan
PRKCQ inhibition enhances chemosensitivity of triple-negative breast cancer by regulating Bim
Jessica H. Byerly, Elisa R. Port, Hanna Y. Irie
Secreted breast tumor interstitial fluid microRNAs and their target genes are associated with triple-negative breast cancer, tumor grade, and immune infiltration
Thilde Terkelsen, Francesco Russo, Pavel Gromov, Vilde Drageset Haakensen, Søren Brunak, Irina Gromova, Anders Krogh, Elena Papaleo
Superior breast cancer metastasis risk stratification using an epithelial-mesenchymal-amoeboid transition gene signature
Amin Emad, Tania Ray, Tor W. Jensen, Meera Parat, Rachael Natrajan, Saurabh Sinha, Partha S. Ray
Progesterone receptor membrane component 1 regulates lipid homeostasis and drives oncogenic signaling resulting in breast cancer progression
Hannah Asperger, Nadia Stamm, Berthold Gierke, Michael Pawlak, Ute Hofmann, Ulrich M. Zanger, Annamaria Marton, Robert L. Katona, Andrea Buhala, Csaba Vizler, Jan-Philipp Cieslik, Eugen Ruckhäberle, Dieter Niederacher, Tanja Fehm, Hans Neubauer, Marina Ludescher
A subset of activated fibroblasts is associated with distant relapse in early luminal breast cancer
Claire Bonneau, Antoine Eliès, Yann Kieffer, Brigitte Bourachot, Sylvain Ladoire, Floriane Pelon, Delphine Hequet, Jean-Marc Guinebretière, Christophe Blanchet, Anne Vincent-Salomon, Roman Rouzier, Fatima Mechta-Grigoriou
Neoadjuvant endocrine therapy in locally advanced estrogen or progesterone receptor-positive breast cancer: determining the optimal endocrine agent and treatment duration in postmenopausal women—a literature review and proposed guidelines
Lauren I. Madigan, Phuong Dinh, J. Dinny Graham
Erythrocyte membrane fatty acids and breast cancer risk by tumor tissue expression of immuno-inflammatory markers and fatty acid synthase: a nested case-control study
Emma E. McGee, Claire H. Kim, Molin Wang, Donna Spiegelman, Daniel G. Stover, Yujing J. Heng, Laura C. Collins, Gabrielle M. Baker, Maryam S. Farvid, Pepper Schedin, Sonali Jindal, Rulla M. Tamimi, A. Heather Eliassen
BRCAness digitalMLPA profiling predicts benefit of intensified platinum-based chemotherapy in triple-negative and luminal-type breast cancer
Esther H. Lips, Anne Benard-Slagter, Mark Opdam, Caroline E. Scheerman, Jelle Wesseling, Frans B. L. Hogervorst, Sabine C. Linn, Suvi Savola, Petra M. Nederlof
Identification and targeting of selective vulnerability rendered by tamoxifen resistance
Madhurendra Singh, Xiaolei Zhou, Xinsong Chen, Gema Sanz Santos, Sylvain Peuget, Qing Cheng, Ali Rihani, Elias S. J. Arnér, Johan Hartman, Galina Selivanova
A risk-associated Active transcriptome phenotype expressed by histologically normal human breast tissue and linked to a pro-tumorigenic adipocyte population
Taekyu Kang, Christina Yau, Christopher K. Wong, John Z. Sanborn, Yulia Newton, Charlie Vaske, Stephen C. Benz, Gregor Krings, Roman Camarda, Jill E. Henry, Josh Stuart, Mark Powell, Christopher C. Benz
Distinct phenotypes of cancer cells on tissue matrix gel
Kelsey F. Ruud, William C. Hiscox, Ilhan Yu, Roland K. Chen, Weimin Li
EFFECT: a randomized phase II study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancer
Laura Biganzoli, Saverio Cinieri, Rossana Berardi, Rebecca Pedersini, Amelia McCartney, Alessandro Marco Minisini, Elena Rota Caremoli, Simon Spazzapan, Emanuela Magnolfi, Antonella Brunello, Emanuela Risi, Raffaella Palumbo, Silvana Leo, Marco Colleoni, Sara Donati, Sabino De Placido, Laura Orlando, Mirco Pistelli, Veronica Parolin, Anna Mislang, Dimitri Becheri, Fabio Puglisi, Giuseppina Sanna, Elena Zafarana, Luca Boni, Giuseppe Mottino
Therapeutic role of recurrent ESR1-CCDC170 gene fusions in breast cancer endocrine resistance
Li Li, Ling Lin, Jamunarani Veeraraghavan, Yiheng Hu, Xian Wang, Sanghoon Lee, Ying Tan, Rachel Schiff, Xiao-Song Wang
Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets
Sasagu Kurozumi, Mansour Alsaleem, Cíntia J. Monteiro, Kartikeya Bhardwaj, Stacey E. P. Joosten, Takaaki Fujii, Ken Shirabe, Andrew R. Green, Ian O. Ellis, Emad A. Rakha, Nigel P. Mongan, David M. Heery, Wilbert Zwart, Steffi Oesterreich, Simon J. Johnston
HER2 expression on tumor-derived extracellular vesicles and circulating tumor cells in metastatic breast cancer
Afroditi Nanou, Leonie Laura Zeune, Francois-Clement Bidard, Jean-Yves Pierga, Leonardus Wendelinus Mathias Marie Terstappen
MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer
Neil Portman, Heloisa H. Milioli, Sarah Alexandrou, Rhiannon Coulson, Aliza Yong, Kristine J. Fernandez, Kee Ming Chia, Ensar Halilovic, Davendra Segara, Andrew Parker, Sue Haupt, Ygal Haupt, Wayne D. Tilley, Alex Swarbrick, C. Elizabeth Caldon, Elgene Lim
Perinatal and postnatal exposures and risk of young-onset breast cancer
Mary V. Diaz-Santana, Katie M. O’Brien, Aimee A. D’Aloisio, Gloria Regalado, Dale P. Sandler, Clarice R. Weinberg
Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer
Neil A. O’Brien, Martina S. J. McDermott, Dylan Conklin, Tong Luo, Raul Ayala, Suruchi Salgar, Kevin Chau, Emmanuelle DiTomaso, Naveen Babbar, Faye Su, Alex Gaither, Sara A. Hurvitz, Ronald Linnartz, Kristine Rose, Samit Hirawat, Dennis J. Slamon
Discordance in 21-gene recurrence scores between paired breast cancer samples is inversely associated with patient age
Sarah M. Bernhardt, Pallave Dasari, Joseph Wrin, Wendy Raymond, Suzanne Edwards, David Walsh, Amanda R. Townsend, Timothy J. Price, Wendy V. Ingman
Clinical implications of prospective genomic profiling of metastatic breast cancer patients
Courtney T. van Geelen, Peter Savas, Zhi Ling Teo, Stephen J. Luen, Chen-Fang Weng, Yi-An Ko, Keilly S. Kuykhoven, Franco Caramia, Roberto Salgado, Prudence A. Francis, Sarah-Jane Dawson, Stephen B. Fox, Andrew Fellowes, Sherene Loi
Immune parameters associated with survival in metaplastic breast cancer
Xue Chao, Lili Liu, Peng Sun, Xia Yang, Mei Li, Rongzhen Luo, Yuhua Huang, Jiehua He, Jingping Yun
MRI background parenchymal enhancement, fibroglandular tissue, and mammographic breast density in patients with invasive lobular breast cancer on adjuvant endocrine hormonal treatment: associations with survival
Roberto Lo Gullo, Isaac Daimiel, Carolina Rossi Saccarelli, Almir Bitencourt, Varadan Sevilimedu, Danny F. Martinez, Maxine S. Jochelson, Elizabeth A. Morris, Jeffrey S. Reiner, Katja Pinker
Impact of a ketogenic diet intervention during radiotherapy on body composition: III—final results of the KETOCOMP study for breast cancer patients
Rainer J. Klement, Colin E. Champ, Ulrike Kämmerer, Petra S. Koebrunner, Kelley Krage, Gabriele Schäfer, M. Weigel, Reinhart A. Sweeney
Hormonal determinants of mammographic density and density change
Marike Gabrielson, Shadi Azam, Elina Hardell, Madeleine Holm, Kumari A. Ubhayasekera, Mikael Eriksson, Magnus Bäcklund, Jonas Bergquist, Kamila Czene, Per Hall
Aspirin use and risk of breast cancer in African American women
Kimberly A. Bertrand, Traci N. Bethea, Hanna Gerlovin, Patricia F. Coogan, Lauren Barber, Lynn Rosenberg, Julie R. Palmer
A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions using 18F-FES PET/CT imaging
Agnes Jager, Elisabeth G. E. de Vries, C. Willemien Menke-van der Houven van Oordt, Patrick Neven, Clasina M. Venema, Andor W. J. M. Glaudemans, Yamei Wang, Rebecca G. Bagley, Maureen G. Conlan, Philippe Aftimos
Plasma thymidine kinase 1 activity and outcome of ER+ HER2− metastatic breast cancer patients treated with palbociclib and endocrine therapy
Luc Cabel, Dan Rosenblum, Florence Lerebours, Etienne Brain, Delphine Loirat, Mattias Bergqvist, Paul Cottu, Anne Donnadieu, Anne Bethune, Nicolas Kiavue, Manuel Rodrigues, Jean-Yves Pierga, Marie-Laure Tanguy, François-Clément Bidard
Independent and joint cross-sectional associations of statin and metformin use with mammographic breast density
Erica J. Lee Argov, Teofilia Acheampong, Mary Beth Terry, Carmen B. Rodriguez, Mariangela Agovino, Ying Wei, Shweta Athilat, Parisa Tehranifar
Outdoor air pollution and terminal duct lobular involution of the normal breast
Nicole M. Niehoff, Alexander P. Keil, Rena R. Jones, Shaoqi Fan, Gretchen L. Gierach, Alexandra J. White
Mammographic density change in a cohort of premenopausal women receiving tamoxifen for breast cancer prevention over 5 years
Adam R. Brentnall, Ruth Warren, Elaine F. Harkness, Susan M. Astley, Julia Wiseman, Jill Fox, Lynne Fox, Mikael Eriksson, Per Hall, Jack Cuzick, D. Gareth Evans, Anthony Howell
Fibroblasts direct differentiation of human breast epithelial progenitors
Mikkel Morsing, Jiyoung Kim, René Villadsen, Nadine Goldhammer, Abbas Jafari, Moustapha Kassem, Ole William Petersen, Lone Rønnov-Jessen
Sunitinib facilitates metastatic breast cancer spreading by inducing endothelial cell senescence
Denian Wang, Fei Xiao, Zhongxue Feng, Min Li, Lingmiao Kong, Luping Huang, Yong’gang Wei, Hongyu Li, Fei Liu, Haili Zhang, Wei Zhang
Association between indicators of systemic inflammation biomarkers during puberty with breast density and onset of menarche
Karin B. Michels, Kristen Keller, Ana Pereira, Claire E. Kim, José L. Santos, John Shepherd, Camila Corvalan, Alexandra M. Binder
Trastuzumab-induced upregulation of a protein set in extracellular vesicles emitted by ErbB2-positive breast cancer cells correlates with their trastuzumab sensitivity
Arik Drucker, Byong Hoon Yoo, Iman Aftab Khan, Dongsic Choi, Laura Montermini, Xiaoyang Liu, Sanja Jovanovic, Tallal Younis, Kirill V. Rosen
Incidence of hypothyroidism after treatment for breast cancer—a Danish matched cohort study
Anne Mette Falstie-Jensen, Buket Ö. Esen, Anders Kjærsgaard, Ebbe L. Lorenzen, Jeanette D. Jensen, Kristin V. Reinertsen, Olaf M. Dekkers, Marianne Ewertz, Deirdre P. Cronin-Fenton
Inter-tumor genomic heterogeneity of breast cancers: comprehensive genomic profile of primary early breast cancers and relapses
Caterina Fumagalli, Alberto Ranghiero, Sara Gandini, Federica Corso, Sergio Taormina, Elisa De Camilli, Alessandra Rappa, Davide Vacirca, Giuseppe Viale, Elena Guerini-Rocco, Massimo Barberis
Haplotype analysis of the internationally distributed BRCA1 c.3331_3334delCAAG founder mutation reveals a common ancestral origin in Iberia
Anna Marie De Asis Tuazon, Paul Lott, Mabel Bohórquez, Jennyfer Benavides, Carolina Ramirez, Angel Criollo, Ana Estrada-Florez, Gilbert Mateus, Alejandro Velez, Jenny Carmona, Justo Olaya, Elisha Garcia, Guadalupe Polanco-Echeverry, Jacob Stultz, Carolina Alvarez, Teresa Tapia, Patricia Ashton-Prolla, Barbara Alemar, Cristina Brinckmann Oliveira Netto, Dirce Maria Carraro, Fernando Regla Vargas, Gustavo Stumpf da Silva, Ivana Lúcia Oliveira Nascimento, Kelly Rose Lobo de Souza, Maria Isabel Achatz, Miguel Angelo Martins Moreira, Maria Betânia Torrales, Maristela Pimenta, Taisa Manuela Bonfim Machado-Lopes, Ana Vega, Conxi Lazaro, Eva Tornero, Cristina Martinez-Bouzas, Mar Infante, Miguel De La Hoya, Orland Diez, Brian L. Browning, Fernando Bolaños, Raúl Murillo, Yesid Sánchez, Carolina Sanabria, Martha Lucia Serrano, John Jairo Suarez, Bruce Rannala, Manuel R. Teixeira, Pilar Carvallo, Magdalena Echeverry, Luis G. Carvajal-Carmona
Circulating growth factor concentrations and breast cancer risk: a nested case-control study of IGF-1, IGFBP-3, and breast cancer in a family-based cohort
Kelsey R. Monson, Mandy Goldberg, Hui-Chen Wu, Regina M. Santella, Wendy K. Chung, Mary Beth Terry
Correction to: Trastuzumab-induced upregulation of a protein set in extracellular vesicles emitted by ErbB2-positive breast cancer cells correlates with their trastuzumab sensitivity
Arik Drucker, Byong Hoon Yoo, Iman Aftab Khan, Dongsic Choi, Laura Montermini, Xiaoyang Liu, Sanja Jovanovic, Tallal Younis, Kirill V. Rosen
Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer—results from the randomized phase III SUCCESS-A trial
Amelie de Gregorio, Lothar Häberle, Peter A. Fasching, Volkmar Müller, Iris Schrader, Ralf Lorenz, Helmut Forstbauer, Thomas W. P. Friedl, Emanuel Bauer, Nikolaus de Gregorio, Miriam Deniz, Visnja Fink, Inga Bekes, Ulrich Andergassen, Andreas Schneeweiss, Hans Tesch, Sven Mahner, Sara Y. Brucker, Jens-Uwe Blohmer, Tanja N. Fehm, Georg Heinrich, Krisztian Lato, Matthias W. Beckmann, Brigitte Rack, Wolfgang Janni
Pubertal timing and breast cancer risk in the Sister Study cohort
Mandy Goldberg, Aimee A. D’Aloisio, Katie M. O’Brien, Shanshan Zhao, Dale P. Sandler
Differential kynurenine pathway metabolism in highly metastatic aggressive breast cancer subtypes: beyond IDO1-induced immunosuppression
Benjamin Heng, Ayse A. Bilgin, David B. Lovejoy, Vanessa X. Tan, Heloisa H. Milioli, Laurence Gluch, Sonia Bustamante, Tharani Sabaretnam, Pablo Moscato, Chai K. Lim, Gilles J. Guillemin
Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study
Joyce O’Shaughnessy, Christine Brezden-Masley, Marina Cazzaniga, Tapashi Dalvi, Graham Walker, James Bennett, Shozo Ohsumi
Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial
Serena Di Cosimo, Luca Porcu, Dominique Agbor-tarh, Saverio Cinieri, Maria Alice Franzoi, Maria Carmen De Santis, Cristina Saura, Jens Huober, Debora Fumagalli, Miguel Izquierdo, Martine Piccart, Maria Grazia Daidone, Evandro de Azambuja
Local and distant tumor dormancy during early stage breast cancer are associated with the predominance of infiltrating T effector subsets
Hussein F. Aqbi, Cara Coleman, Melika Zarei, Saeed H. Manjili, Laura Graham, Jennifer Koblinski, Chunquing Guo, Yibin Xie, Georgi Guruli, Harry D. Bear, Michael O. Idowu, Mehran Habibi, Xiang-Yang Wang, Masoud H. Manjili
COVID-19: a potential driver of immune-mediated breast cancer recurrence?
Federica Francescangeli, Maria Laura De Angelis, Ann Zeuner
Use of nonsteroidal anti-inflammatory drugs and breast cancer risk in a prospective cohort of postmenopausal women
Manon Cairat, Marie Al Rahmoun, Marc J. Gunter, Gianluca Severi, Laure Dossus, Agnès Fournier
Prognostic value of 18F-FDG PET and PET/CT for assessment of treatment response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis
Sangwon Han, Joon Young Choi
Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer
Ana C. Garrido-Castro, Cristina Saura, Romualdo Barroso-Sousa, Hao Guo, Eva Ciruelos, Begoña Bermejo, Joaquin Gavilá, Violeta Serra, Aleix Prat, Laia Paré, Pamela Céliz, Patricia Villagrasa, Yisheng Li, Jennifer Savoie, Zhan Xu, Carlos L. Arteaga, Ian E. Krop, David B. Solit, Gordon B. Mills, Lewis C. Cantley, Eric P. Winer, Nancy U. Lin, Jordi Rodon
A comprehensive overview of metaplastic breast cancer: clinical features and molecular aberrations
Tejaswini P. Reddy, Roberto R. Rosato, Xiaoxian Li, Stacy Moulder, Helen Piwnica-Worms, Jenny C. Chang
A tumour suppressive relationship between mineralocorticoid and retinoic acid receptors activates a transcriptional program consistent with a reverse Warburg effect in breast cancer
Tram B. Doan, Vanessa Cheung, Colin D. Clyne, Heidi N. Hilton, Natalie Eriksson, Morag J. Young, John W. Funder, George E. O. Muscat, Peter J. Fuller, Christine L. Clarke, J. Dinny Graham
CYP27A1 expression is associated with risk of late lethal estrogen receptor-positive breast cancer in postmenopausal patients
Siker Kimbung, Maria Inasu, Tor Stålhammar, Björn Nodin, Karin Elebro, Helga Tryggvadottir, Maria Ygland Rödström, Karin Jirström, Karolin Isaksson, Helena Jernström, Signe Borgquist
Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial
Miguel Quintela-Fandino, Esther Holgado, Luis Manso, Serafin Morales, Begoña Bermejo, Ramon Colomer, Juan V. Apala, Raquel Blanco, Manuel Muñoz, Eduardo Caleiras, Vega Iranzo, Mario Martinez, Orlando Dominguez, Javier Hornedo, Lucia Gonzalez-Cortijo, Javier Cortes, Ariadna Gasol Cudos, Diego Malon, Antonio Lopez-Alonso, María C. Moreno-Ortíz, Silvana Mouron, Santos Mañes
CRIPTO antagonist ALK4L75A-Fc inhibits breast cancer cell plasticity and adaptation to stress
Ozlen Balcioglu, Richard E. Heinz, David W. Freeman, Brooke L. Gates, Berhane M. Hagos, Evan Booker, Elnaz Mirzaei Mehrabad, Hyrum T. Diesen, Kishan Bhakta, Supraja Ranganathan, Masami Kachi, Mathias Leblanc, Peter C. Gray, Benjamin T. Spike
Activating transcription factor-2 (ATF2) is a key determinant of resistance to endocrine treatment in an in vitro model of breast cancer
Athina Giannoudis, Mohammed Imad Malki, Bharath Rudraraju, Hisham Mohhamed, Suraj Menon, Triantafillos Liloglou, Simak Ali, Jason S. Carroll, Carlo Palmieri
Quadruple-negative breast cancer: novel implications for a new disease
Shristi Bhattarai, Geetanjali Saini, Keerthi Gogineni, Ritu Aneja
Extracellular vesicles from young women’s breast cancer patients drive increased invasion of non-malignant cells via the Focal Adhesion Kinase pathway: a proteomic approach
Kimberly R. Jordan, Jessica K. Hall, Troy Schedin, Michelle Borakove, Jenny J. Xian, Monika Dzieciatkowska, Traci R. Lyons, Pepper Schedin, Kirk C. Hansen, Virginia F. Borges
Use of postmenopausal hormone therapies and risk of histology- and hormone receptor-defined breast cancer: results from a 15-year prospective analysis of NIH-AARP cohort
Shao-Ming Wang, Ruth M. Pfeiffer, Gretchen L. Gierach, Roni T. Falk
Combined the SMAC mimetic and BCL2 inhibitor sensitizes neoadjuvant chemotherapy by targeting necrosome complexes in tyrosine aminoacyl-tRNA synthase-positive breast cancer
Kyung-Min Lee, Hyebin Lee, Dohyun Han, Woo Kyung Moon, Kwangsoo Kim, Hyeon Jeong Oh, Jinwoo Choi, Eun Hye Hwang, Seong Eun Kang, Seock-Ah Im, Kyung-Hun Lee, Han Suk Ryu
Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastases
Jose Pablo Leone, Kyrre E. Emblem, Michelle Weitz, Rebecca S. Gelman, Bryan P. Schneider, Rachel A. Freedman, Jerry Younger, Marco C. Pinho, A. Gregory Sorensen, Elizabeth R. Gerstner, Gordon Harris, Ian E. Krop, Daniel Morganstern, Jessica Sohl, Jiani Hu, Elizabeth Kasparian, Eric P. Winer, Nancy U. Lin
Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancer
Jason J. Zoeller, Aleksandr Vagodny, Veerle W. Daniels, Krishan Taneja, Benjamin Y. Tan, Yoko S. DeRose, Maihi Fujita, Alana L. Welm, Anthony Letai, Joel D. Leverson, Vincent Blot, Roderick T. Bronson, Deborah A. Dillon, Joan S. Brugge
Mutant p53 drives the loss of heterozygosity by the upregulation of Nek2 in breast cancer cells
Amr Ghaleb, Malik Padellan, Natalia Marchenko
Immune phenotype of patients with stage IV metastatic inflammatory breast cancer
Sandra V. Fernandez, Alexander W. MacFarlane IV, Mowafaq Jillab, Maria F. Arisi, Jennifer Yearley, Lakshmanan Annamalai, Yulan Gong, Kathy Q. Cai, R. Katherine Alpaugh, Massimo Cristofanilli, Kerry S. Campbell
Shotgun proteomics coupled to nanoparticle-based biomarker enrichment reveals a novel panel of extracellular matrix proteins as candidate serum protein biomarkers for early-stage breast cancer detection
Claudia Fredolini, Khyatiben V. Pathak, Luisa Paris, Kristina M. Chapple, Kristine A. Tsantilas, Matthew Rosenow, Tony J. Tegeler, Krystine Garcia-Mansfield, Davide Tamburro, Weidong Zhou, Paul Russo, Samuele Massarut, Francesco Facchiano, Claudio Belluco, Ruggero De Maria, Enrico Garaci, Lance Liotta, Emanuel F. Petricoin, Patrick Pirrotte
Integrin alpha-2 and beta-1 expression increases through multiple generations of the EDW01 patient-derived xenograft model of breast cancer—insight into their role in epithelial mesenchymal transition in vivo gained from an in vitro model system
Razan Wafai, Elizabeth D. Williams, Emma de Souza, Peter T. Simpson, Amy E. McCart Reed, Jamie R. Kutasovic, Mark Waltham, Cameron E. Snell, Tony Blick, Erik W. Thompson, Honor J. Hugo
Telomere lengths in women treated for breast cancer show associations with chemotherapy, pain symptoms, and cognitive domain measures: a longitudinal study
Areej A. Alhareeri, Kellie J. Archer, Han Fu, Debra E. Lyon, R. K. Elswick Jr, Debra L. Kelly, Angela R. Starkweather, Lynne W. Elmore, Yahya A. Bokhari, Colleen K. Jackson-Cook
Association of breast cancer with MRI background parenchymal enhancement: the IMAGINE case-control study
Gordon P. Watt, Janice Sung, Elizabeth A. Morris, Saundra S. Buys, Angela R. Bradbury, Jennifer D. Brooks, Emily F. Conant, Susan P. Weinstein, Despina Kontos, Meghan Woods, Sarah V. Colonna, Xiaolin Liang, Matthew A. Stein, Malcolm C. Pike, Jonine L. Bernstein
Cathepsin V suppresses GATA3 protein expression in luminal A breast cancer
Naphannop Sereesongsaeng, Sara H. McDowell, James F. Burrows, Christopher J. Scott, Roberta E. Burden
Tumour-infiltrating lymphocytes as a prognostic and tamoxifen predictive marker in premenopausal breast cancer: data from a randomised trial with long-term follow-up
Christine Lundgren, Pär-Ola Bendahl, Maria Ekholm, Mårten Fernö, Carina Forsare, Ute Krüger, Bo Nordenskjöld, Olle Stål, Lisa Rydén